Screener
Halozyme Therapeutics HALO Accounts Receivable
Accounts Receivable at other companies
Segments
By product
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
FAQ
- What is Halozyme Therapeutics's accounts receivable?
- Halozyme Therapeutics (HALO) reported accounts receivable of $453.33M in Q2 2026.
- How has Halozyme Therapeutics's accounts receivable changed year-over-year?
- Halozyme Therapeutics's accounts receivable increased by 43.9% year-over-year, from $315.07M to $453.33M.
- What is the long-term trend for Halozyme Therapeutics's accounts receivable?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's accounts receivable has grown at a 34.0% compound annual growth rate (CAGR), from $98.73M to $426.27M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.
Ask your AI about Halozyme Therapeutics's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude